| Title |
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
|
|---|---|
| Published in |
Vascular Health and Risk Management, November 2012
|
| DOI | 10.2147/vhrm.s37969 |
| Pubmed ID | |
| Authors |
Steve Brunell, Peter Toth, Ramirez, Cobble, Robert Chilton, Chiquette |
| Abstract |
Cyslipidemia and type 2 diabetes are two of the most significant risk factors for the development of cardiovascular disease. Measurement of lipoprotein subclasses provides important information about derangements in lipid metabolism and helps refine cardiovascular risk assessment. Exenatide, a glucagon-like peptide 1 receptor agonist, improved glycemic control, obesity, hypertension, and dyslipidemia in patients with type 2 diabetes in clinical trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 118 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Greece | 1 | <1% |
| Denmark | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 114 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 14% |
| Researcher | 14 | 12% |
| Student > Postgraduate | 12 | 10% |
| Student > Bachelor | 11 | 9% |
| Other | 10 | 8% |
| Other | 21 | 18% |
| Unknown | 33 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 8% |
| Nursing and Health Professions | 8 | 7% |
| Agricultural and Biological Sciences | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Other | 8 | 7% |
| Unknown | 37 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2023.
All research outputs
#4,835,465
of 25,373,627 outputs
Outputs from Vascular Health and Risk Management
#156
of 804 outputs
Outputs of similar age
#35,741
of 202,248 outputs
Outputs of similar age from Vascular Health and Risk Management
#3
of 9 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,248 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.